FPH updates FY26 revenue and earnings guidance

Monday 23rd February 2026

Auckland, New Zealand, 23 February 2026 – Fisher & Paykel Healthcare Corporation Limited announced today that it has updated its revenue and earnings guidance for the financial year ending 31 March 2026.

The full-year guidance previously provided on 29 November 2025, based on a NZ:US exchange rate of 57 cents, was for operating revenue to be in the range of approximately $2.17 billion to $2.27 billion and full-year net profit after tax to be in the range of approximately $410 million to $460 million.

At 31 January exchange rates*, the company now expects full year operating revenue to be approximately $2.30 billion, and net profit after tax is expected to be in the range of approximately $450 million to $470 million. This updated guidance does not incorporate any potential refund of US tariffs paid to date during the 2026 financial year.

“We have continued to see good growth across the full range of our Hospital products so far during our second half,” said Lewis Gradon, Managing Director and CEO.

“While relative seasonal respiratory hospitalisations in the Northern Hemisphere winter may continue to impact the second half result, our performance to date suggests pleasing progress in our efforts to change clinical practice. Continuous improvement activities and other efficiency gains are also contributing to improvements in our gross margin and operating margin,” said Mr Gradon.

The company also notes that the United States Supreme Court announced it has invalidated tariffs imposed by the US administration under the International Emergency Economic Powers Act (IEEPA). There are still a number of uncertainties regarding the implications of the Supreme Court’s ruling for companies that import into the United States. The company continues to work through the complexities associated with the US court rulings, refund processes and application of free trade agreements and the Nairobi Protocol to its products, and will provide an update on tariff impacts with its full year results at the end of May.

The company continues to view current and proposed tariff structures in the context of cost increases that will be mitigated over time by the company’s longstanding continuous improvement activities. As such, the company does not currently believe these matters have any material impact on the company’s long-term direction, strategy or sustainable profitable growth.

* At 31 January 2026 exchange rates of NZD:USD 0.60, NZD:EUR 0.51, NZD:MXN 10.44.

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

FPH updates FY26 revenue and earnings guidance

Comments from our readers

No comments yet